A woman with a bad skin reaction switched to an older lung cancer pill and did well
Original title: Gefitinib treatment after exfoliative dermatitis induced by sequential aumolertinib and furmonertinib in lung adenocarcinoma: a case report.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is a report on a single patient using pills that already exist, not a study that proves this switch works for others.
The short version
One woman had a severe skin reaction to newer lung cancer pills, so her doctors switched her to an older pill, and it worked without the rash coming back.
What was studied. This is a report about one patient. She was a 74-year-old woman with lung adenocarcinoma that had spread to her brain. Her cancer had an EGFR exon 21 L858R change.
What they found. She took two newer EGFR-TKI pills, aumolertinib and then furmonertinib. On these, she got severe exfoliative dermatitis, a serious skin reaction where the skin peels. Her doctors switched her to gefitinib, an older EGFR-TKI pill. She tolerated it well, the skin reaction did not come back, and scans showed her disease stayed stable for more than four months.
What this means, and what it doesn't
What it could mean: If a newer EGFR pill causes a severe skin reaction, an older pill may be an option worth asking your doctor about. It may control the cancer without the same skin problem. It also shows why any bad skin reaction on these pills needs to be reported to your care team right away.
What it doesn't mean: This is one patient's story, not a study. Doctors call this a case report. It cannot tell us how often this works or who else it would help. What worked for her may not work for someone else. It is not a cure, and it is not a new treatment. It does not change what is recommended for most people.
Source: PubMed, July 15, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.